<DOC>
	<DOCNO>NCT00993226</DOCNO>
	<brief_summary>The objective identify optimal dose SABER-Bupivacaine postoperative pain control patient undergo hysterectomy basis pharmacokinetics , efficacy safety evaluation . The study duration consist screen period 14 day treatment period 14 day long term follow visit 6 month . The study provide data efficacy safety product .</brief_summary>
	<brief_title>An International Trial Evaluate Efficacy Safety SABER-Bupivacaine Postoperative Pain Control Patients Undergoing Hysterectomy</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>A planned elective , abdominal hysterectomy Patients suitable general anaesthesia Known clinically significant hepatic , gastrointestinal , renal , haematological , urologic , neurological , respiratory , endocrine cardiovascular system abnormality Known serious uncontrolled illness : cancer , psychiatric metabolic disturbance . History cure localised malignancy allow ( i.e . basal squamous cell skin carcinoma , breast carcinoma cervical carcinoma ) Abnormal ECG Prolonged QT syndrome Current regular use analgesic medication indication ( )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Postoperative pain</keyword>
	<keyword>Local anaesthesia</keyword>
	<keyword>Postoperative pain open abdominal hysterectomy surgery</keyword>
</DOC>